AI Insight
Researchers at St. Jude Children's Research Hospital have demonstrated that inhibiting menin, a protein known to support leukemia growth, shows therapeutic potential for treating myeloproliferative neoplasms. In preclinical models, menin inhibition significantly extended survival and reversed multiple disease characteristics. The study builds on existing menin-targeted therapies already being developed for certain leukemia types.
Why it matters
This research expands the potential therapeutic applications of menin inhibitors beyond their current use in leukemia treatment to include myeloproliferative neoplasms, a group of blood cancers with limited treatment options. The preclinical success suggests a pathway toward new treatment strategies for patients with these disorders.
Understand the Science
Inhibiting menin, a protein that supports leukemia growth and is already targeted to treat some forms of leukemia, also holds promise for treating myeloproliferative neoplasms. A new study from scientists at St. Jude Children’s Research Hospital showed that inhibiting menin significantly extended survival and reversed multiple disease features in preclinical models. The findings were published today in Cancer Cell.
Source: Inhibiting protein to treat myeloproliferative neoplasms shows preclinical promise